Lucence Diagnostics Presents LiquidHALLMARK® at ESMO Asia 2018 Congress

November 27, 2018

Lucence Diagnostics was delighted to participate in the ESMO Asia 2018 Congress organized by the European Society for Medical Oncology in Singapore from November 23-25, 2018.

At ESMO Asia, we presented our flagship liquid biopsy test, LiquidHALLMARK® – the world’s first blood test to span multiple cancer-causing mutations and viruses – to the oncologists in attendance. LiquidHALLMARK® helps to improve diagnosis and determine the most appropriate treatment for cancer patients. It can also help to monitor treatment response and risk of cancer recurrence.

We were glad to share with Dr Lam Pin Min, Senior Minister of State for Health and Transport for Singapore and Guest-of-Honor of ESMO Asia, about Lucence’s efforts to reducing avoidable cancer deaths through our proprietary liquid biopsy technology.

ESMO Asia is the largest medical conference connecting European and Asian oncologists to the latest advances in cancer care. Lucence is proud to be a part of this year’s event and look forward to future knowledge sharing opportunities with oncology professionals in Europe and the region.



Dr Lam Pin Min, Senior Minister of State for Health and Transport with Dr Min-Han Tan, CEO and Medical Director of Lucence Diagnostics at ESMO Asia 2018.


Team Lucence at ESMO Asia 2018.


Our account manager chatting with oncologists at ESMO Asia 2018.


Need Help?